AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

MarketsPricingSign inSign up free

NATALIZUMAB

4 registrations across 3 African markets— 3 active

Markets with NATALIZUMAB

🇲🇦Morocco
2 registrations
2 active
🇹🇳Tunisia
1 registration
0 active
🇿🇦South Africa
1 registration
1 active

Recent registrations

Brand / ProductMarketHolderStatusExpires
TYSABRI 300 MG
Solution injectable pour perfusion / 20 mg/ml
🇹🇳TunisiaBIOGEN Idec LtdexpiredOct 2020
TYSABRI🇿🇦South AfricaACINO PHARMA (PTY) LTDactiveJan 1900
TYSABRI 300MG
SOLUTION A DILUER POUR PERFUSION
🇲🇦Morocco—active—
TYSABRI 300MG
SOLUTION A DILUER POUR PERFUSION
🇲🇦Morocco—active—

NATALIZUMAB in Africa — Regulatory Overview

NATALIZUMAB is registered across 3 African markets with 4 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Morocco, Tunisia, South Africa. AfricaRegulatory refreshes this data daily from official government sources.

Of the 4 registrations, 3 (75%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.